Weight-based vs fixed dosing of darbepoetin alfa for anemia following kidney transplantation
CONCLUSION: Weight-based and fixed dosing approaches for darbepoetin alfa were not different in the achievement of a hemoglobin concentration of at least 10 g/dL without blood transfusion at 12 weeks after darbepoetin alfa initiation, with significantly lower cumulative darbepoetin alfa utilization in the weight-based group. Weight-based dosing of darbepoetin alfa in PTA appears to be safe and effective, with the potential for significant patient and health-system cost savings.PMID:37471466 | DOI:10.1093/ajhp/zxad163
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Jonathan Solis Nicole Wilson Teena Sam Tsung-Wei Ma Angelito Yango Bernard Fischbach Ann D Kataria Source Type: research
More News: Anemia | Aranesp | Blood Transusion | Drugs & Pharmacology | Insurance | Kidney Transplant | Kidney Transplantation | Study | Transplant Surgery | Transplants | Urology & Nephrology